Chunrong Tong
YOU?
Author Swipe
View article: Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation
Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation Open
Not available.
View article: Five-year Outcome of CD19 Combined With CD22 CAR-T Cell Therapy in Patients With B-ALL Relapsed After Allo-transplantation
Five-year Outcome of CD19 Combined With CD22 CAR-T Cell Therapy in Patients With B-ALL Relapsed After Allo-transplantation Open
View article: P387: THE TREATMENT RESPONSE OF A TWO-DOSE REGIMEN OF DOSE-ADJUSTED INOTUZUMAB IN RELAPSED/REFRACTORY B-ALL
P387: THE TREATMENT RESPONSE OF A TWO-DOSE REGIMEN OF DOSE-ADJUSTED INOTUZUMAB IN RELAPSED/REFRACTORY B-ALL Open
Background: CD19- or CD22-specific chimeric antigen receptor (CAR) T-cell therapy resulted in promising outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). However, some patients relapse after CAR-T and usually…
View article: Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy Open
Chimeric antigen receptor (CAR)-T cell therapy provides an effective salvage treatment for relapsed/refractory multiple myeloma (RRMM) patients. End-stage RRMM with plasma cell leukemia (PCL) transformation is highly aggressive and resista…
View article: <scp>CAR‐T</scp> therapy as a consolidation in remission <scp>B‐ALL</scp> patients with poor prognosis
<span>CAR‐T</span> therapy as a consolidation in remission <span>B‐ALL</span> patients with poor prognosis Open
Background To date, almost all studies regarding chimeric antigen receptor (CAR)‐T cell therapy for B‐cell acute lymphoblastic leukemia (B‐ALL) were performed in refractory/relapsed (r/r) or minimal residual disease‐positive patients. CAR‐…
View article: Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy Open
Background For CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) after treatment with murine CD19 (mCD19) CAR-T, the reinfusion of mCD19 CAR-T cells may be ineffective due to anti-mouse single-chain variable…
View article: Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL Open
View article: Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma Open
Single antigen–targeted chimeric antigen receptor (CAR) T-cell therapy may be insufficient to induce a durable response in pediatric aggressive B-cell lymphomas. This clinical trial examined the feasibility of sequential different B-cell a…
View article: Combination of <scp>CD19</scp> and <scp>CD22 CAR‐T</scp> cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation
Combination of <span>CD19</span> and <span>CD22 CAR‐T</span> cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation Open
The prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic transplantation is dismal when treated with conventional approaches. While single‐target CD19 or CD22 chimeric antigen receptor (CAR) T‐cell therapy has achieved…
View article: Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia Open
View article: Post-HSCT relapsed precursor B-cell ALL successfully salvaged by BiTE followed by consolidation CAR-T cell therapy: A report of two cases
Post-HSCT relapsed precursor B-cell ALL successfully salvaged by BiTE followed by consolidation CAR-T cell therapy: A report of two cases Open
Precursor B-cell acute lymphoblastic leukemia (pre-B ALL) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) typically has poor outcomes. Both bispecific T-cell engager (BiTE, blinatumomab) and chimeric antigen recepto…
View article: Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL Open
Pan and colleagues report one of the first prospective evaluations of planned sequential chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and then CD22 in a phase 1 trial, indicating acceptable toxicity and encouraging durable…
View article: CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia Open
Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent problem to be solved. We conducted a CD22 CAR T-cell therapy in 34 relapsed or refrac…
View article: Germline cytotoxic lymphocytes defective mutations in Chinese patients with lymphoma
Germline cytotoxic lymphocytes defective mutations in Chinese patients with lymphoma Open
Certain patients with lymphoma may harbor mutations in perforin 1 (PRF1), unc-13 homolog D (UNC13D), syntaxin 11 (STX11), STXBP2 (syntaxin binding protein 2) or SH2 domain containing 1A (SH2D1A), which causes functional defects of cytotoxi…
View article: Maternal onset de novo SH2D1A mutation and lymphocytic choriomeningitis virus infection in a patient with X-linked lymphoproliferative disease type 1: A case report
Maternal onset de novo SH2D1A mutation and lymphocytic choriomeningitis virus infection in a patient with X-linked lymphoproliferative disease type 1: A case report Open
X‑linked lymphoproliferative disease type 1 (XLP1) is a rare genetic immunodeficiency disease, which occurs due to germline mutations in the SH2D1A gene. This gene has been reported to encode the adaptor molecule signaling lymphocytic acti…